Gilead Sciences Inc

Latest Results (22.10.2025):

Gilead Sciences Inc reported its second quarter of 2025 with a 2% increase in total revenue to $7.1 billion compared to the same period in 2024. The company experienced strong growth driven by its diverse product portfolio, including significant sales increases in Biktarvy and Descovy. Additionally, Gilead raised its full-year revenue and earnings guidance, reflecting confidence in continued innovation and market performance.

Revenue Growth

Total revenue for the second quarter of 2025 rose by 2% to $7.1 billion year-over-year. Excluding Veklury, product sales increased by 4% to $6.9 billion, driven primarily by higher sales in HIV treatments, Livdelzi, and Trodelvy.

Earnings Per Share

Gilead reported diluted earnings per share (EPS) of $1.56, up from $1.29 in the second quarter of 2024. Non-GAAP diluted EPS remained steady at $2.01, reflecting balanced growth and controlled expenses.

Product Sales Highlights

Biktarvy sales surged by 9% to $3.5 billion, while Descovy saw a 35% increase to $653 million. Despite a 44% decline in Veklury sales due to reduced COVID-19 hospitalizations, overall product performance remained robust.

Cash and Shareholder Returns

As of June 30, 2025, Gilead held $7.1 billion in cash and equivalents. The company generated $827 million in operating cash flow and returned $994 million to shareholders through dividends, along with $527 million in stock repurchases.

Guidance and Outlook

For the full year, Gilead has raised its revenue guidance to a range of $28.3 billion to $28.7 billion, up from the previous forecast of $28.2 billion to $28.6 billion. Diluted EPS guidance has also been increased to between $5.85 and $6.15, reflecting strong performance expectations.